GLP-1 receptor agonists have shown great success in supporting weight loss and controlling appetite
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely used for the treatment of T2DM and promote weight loss in individuals with obesity, have demonstrated significant cardiovascular benefits
thus, they are an attractive therapeutic option for patients with type 2 diabetes, especially those with existing cardiovascular disease or at high risk for those complications
For the most current information, use our online search above
Healthcare professionals must carefully weigh potential benefits against risks, ensure appropriate monitoring, and maintain realistic expectations about outcomes
GLP-1s could redefine metabolic health for lakhs of Indians if used correctly